• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Expert opinion on biological therapy >Selective delivery of therapeutic agents for the diagnosis and treatment of cancer.
【24h】

Selective delivery of therapeutic agents for the diagnosis and treatment of cancer.

机译：选择性递送治疗剂以诊断和治疗癌症。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Research activity aimed towards achieving specific and targeted delivery of cancer therapeutics has expanded tremendously in the last decade, resulting in new ways of directing drugs to tumours, as well as new types of drugs. The available strategies exploit differences in the nature of normal and cancer cells and their microenvironment. The discovery and validation of cancer-associated markers, as well as corresponding ligands, is pivotal for developing selective delivery technology for cancer. Although most current clinical trials are either monoclonal antibody- or gene-based, methodological advances in combinatorial libraries of peptides, single chain variable fragments and small organic molecules are expected to change this scenario in the near future. Nanotechnology platforms today allow systematic and modular combinations of therapeutic agents and tumour-binding moieties that may generate novel, personalised agents for selective delivery in cancer. This paper discusses recent developments and future prospects of targeted delivery technologies in the management of cancer.
机译：在过去的十年中，旨在实现癌症治疗剂的特异性和靶向递送的研究活动已经大大扩展，从而产生了将药物导向肿瘤的新方法以及新型药物。可用的策略利用了正常细胞和癌细胞及其微环境的性质差异。癌症相关标记以及相应配体的发现和验证对于开发癌症选择性递送技术至关重要。尽管当前大多数临床试验都是基于单克隆抗体或基于基因的，但肽，单链可变片段和有机小分子组合文库的方法学进步有望在不久的将来改变这种情况。如今，纳米技术平台允许治疗剂和肿瘤结合部分的系统和模块化组合，这些组合可能会产生新颖的，个性化的药物，用于癌症的选择性递送。本文讨论了靶向递送技术在癌症治疗中的最新发展和未来前景。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号